Twist Bioscience因抗体发现平台许可协议而崛起

2026-02-18 01:05

Shares of Twist Bioscience (TWST) spiked on Tuesday after the company announced a cash-and-stock transaction to obtain licensing rights to an antibody discovery platform developed by Invenra, a Madison, Wisconsin-based biotech firm.
As part of the agreement, Twist (TWST), along with Invenra, becomes a co-exclusive provider of Invenra’s B-Body bispecific antibody platform, broadening the company’s existing antibody discovery services.
Per the terms, Invenra will receive $5M upfront in cash and $15M worth of Twist’s (TWST) common stock in addition to a 20% royalty on all license revenue related to the B-Body platform.
In a secondary transaction, Twist (TWST) will purchase preferred stock from existing Invenra stockholders to hold roughly 6% ownership in its partner company in exchange for $13.8M of its common stock.

More on Twist Bioscience